Executive Masterclass 4 - The Great Health Recalibration (2027–2030): What Leaders Must Get Right Next

The end of 2026 marks a clear inflection point for healthcare. The forces that have dominated the last several years — AI at scale, metabolic medicines, women’s health innovation, behavioral health integration, and real-world evidence — are no longer emerging trends. They are becoming the operating reality for every health system, life sciences company, payer, and technology partner.

As the capstone of our Executive Masterclass series, this exclusive, member-only session brings together cross-sector CEOs to define the new rules of strategy, collaboration, risk-taking, and value creation for the 2027–2030 period. Panelists will examine what truly changes once AI is operational at enterprise and clinical scale, how next-generation metabolic therapies are reshaping demand and economics, and why women’s health and behavioral health have moved from the margins to the center of growth strategies.

Designed for senior decision-makers, the discussion provides a forward-looking, unifying framework for navigating the next three years — and for aligning organizations around the structural shifts that will define healthcare’s most consequential transition in decades.

Join us to discuss:

• What AI at enterprise scale actually unlocks once clinical, operational, and regulatory systems stabilize.

• How GLP-1s and next-generation metabolic medicines are redefining service lines, payer dynamics, and consumer behavior.

• Why women’s health and mental health are now foundational growth pillars rather than niche opportunities.

• What “health consumers” will expect between 2027 and 2030 — and how those expectations force redesign across the entire value chain.

• How leaders can balance speed of innovation with the realities of organizational change.